×
About 295 results

ALLMedicine™ Autoimmune Blistering Diseases Center

Research & Reviews  104 results

Eosinophil-rich linear IgA bullous dermatosis induced by mRNA COVID-19 booster vaccine.
https://doi.org/10.1111/cup.14305
Journal of Cutaneous Pathology; Nahm WJ, Juarez M et. al.

Aug 5th, 2022 - We present a case of eosinophil-rich linear IgA bullous disease (LABD) following administration of an mRNA COVID-19 booster vaccine. A 66-year-old man presented to the Emergency Department with a 3-week history of a pruritic blistering rash charac...

Clinical severity scores as a guide for prediction of initial treatment responses in pe...
https://doi.org/10.1111/1346-8138.16532
The Journal of Dermatology; Tanaka R, Kurihara Y et. al.

Aug 2nd, 2022 - Pemphigus and pemphigoid are autoimmune blistering diseases that affect mucosa and skin. Several clinical scoring systems, including the pemphigus disease area index (PDAI) and the bullous pemphigoid disease area index (BPDAI), have been validated...

Pemphigus Vulgaris Aggravated: Rifampicin Found at the Scene of the Crime.
https://doi.org/10.12788/cutis.0526
Cutis Hu L, Sun Y et. al.

Jul 21st, 2022 - Pemphigus vulgaris (PV) is a rare life-threatening condition of the pemphigus group of autoimmune blistering diseases. Systemic glucocorticoids are the cornerstone of management for PV, but complications can arise from their long-term use. We repo...

Updated S2 K guidelines for the management of bullous pemphigoid initiated by the Europ...
https://doi.org/10.1111/jdv.18220
Journal of the European Academy of Dermatology and Venere... Borradori L, Van Beek N et. al.

Jun 30th, 2022 - Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or, most frequently, generalized bullous lesion...

A review of IL-36: an emerging therapeutic target for inflammatory dermatoses.
https://doi.org/10.1080/09546634.2022.2067819
The Journal of Dermatological Treatment; Hwang J, Rick J et. al.

Apr 27th, 2022 - IL-36 cytokines are members of the IL-1 superfamily. Increasing evidence in the IL-36 pathway demonstrates their potential as a therapeutic target for treating inflammatory skin diseases, such as generalized pustular psoriasis (GPP). A narrative r...

see more →

Guidelines  3 results

European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, ini...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518905
Journal of the European Academy of Dermatology and Venere... Schmidt E, Rashid H et. al.

Jul 27th, 2021 - This guideline has been initiated by the task force Autoimmune Blistering Diseases of the European Academy of Dermatology and Venereology, including physicians from all relevant disciplines and patient organizations. It is a S3 consensus-based gui...

European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, ini...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457055
Journal of the European Academy of Dermatology and Venere... Rashid H, Lamberts A et. al.

Jul 11th, 2021 - This guideline on mucous membrane pemphigoid (MMP) has been elaborated by the Task Force for Autoimmune Blistering Diseases of the European Academy of Dermatology and Venereology (EADV) with a contribution of physicians from all relevant disciplin...

Japanese guidelines for the management of pemphigus.
https://doi.org/10.1111/1346-8138.12486
The Journal of Dermatology; , Amagai M et. al.

Jun 10th, 2014 - The Committee for Guidelines for the Management of Pemphigus was organized as one element of the Japanese Dermatological Association (JDA) and the Ministry of Health, Labour, and Welfare (MHLW) Research Project on Measures for Research Committee f...

see more →

Clinicaltrials.gov  2 results

Autoimmune Blistering Diseases Study
https://clinicaltrials.gov/ct2/show/NCT02753777

Feb 14th, 2022 - The disease severity instruments for pemphigus and BP, the Pemphigus Disease Area Index (PDAI) and the Bullous Pemphigoid Disease Area Index (BPDAI), respectively, have the potential to capture changes in all grades of disease activity, including ...

Rituximab in the Treatment of Patients With Bullous Pemphigoid
https://clinicaltrials.gov/ct2/show/NCT00286325

Apr 11th, 2013 - Bullous pemphigoid (BP) is an autoimmune blistering disease characterized clinically by the presence of severely itchy, tense blisters located over the trunk and extremities. BP is the most common of the autoimmune blistering diseases with an inci...

see more →

News  9 results

Adolescence does not rule out bullous pemphigoid
https://www.mdedge.com/internalmedicine/article/194144/dermatology/adolescence-does-not-rule-out-bullous-pemphigoid?channel=39313
M. Alexander Otto

Feb 8th, 2019 - Include bullous pemphigoid in the differential diagnosis of autoimmune blistering diseases in adolescents. Dr.

Adolescence does not rule out bullous pemphigoid
https://www.mdedge.com/pediatrics/article/194144/dermatology/adolescence-does-not-rule-out-bullous-pemphigoid
M. Alexander Otto

Feb 8th, 2019 - Include bullous pemphigoid in the differential diagnosis of autoimmune blistering diseases in adolescents. Dr.

Immunologic testing is key to diagnosing autoimmune blistering diseases
https://www.mdedge.com/internalmedicine/article/147610/medical-dermatology/immunologic-testing-key-diagnosing-autoimmune
Jim Kling

Sep 21st, 2017 - SAN FRANCISCO – Blistering diseases are easily misdiagnosed and may resemble psoriasis or other conditions, but a routine histology and clinical examination aren’t sufficient diagnostic starting points. “You have to have some kind of immunological.

Current Tx for blistering disorders lacks evidence-based science
https://www.mdedge.com/internalmedicine/article/113641/rare-diseases/current-tx-blistering-disorders-lacks-evidence-based
Doug Brunk

Sep 6th, 2016 - NEWPORT BEACH, CALIF. – Current treatment of autoimmune blistering diseases is not backed by evidence-based medicine and solid randomized, controlled trials, according to David T.

see more →